Calico Biosystems gets the CHF 150,000 Kick to predict drug efficacy in cancer patients
25.06.2024
Calico Biosystems is dedicated to enhancing the clinical efficacy of anti-cancer drugs during the pre-clinical stage. It received the final CHF 150,000 kick from Venture Kick to advance the commercialisation of its precision oncology platform for combination therapy.
 Calico Biosystems' Co-Founders
|
 |
The high failure rate of therapeutics, amounting to over 95%, and the limited patient response to approved cancer treatments highlight the urgent need for an advance in therapeutic testing. Calico Biosystems combines experimental and digital methods to evaluate the efficacy of treatments in patient tumors directly, thus overcoming current models that are too artificial to faithfully reproduce their complexity. In addition, its digital strategy uses computational modeling to predict the most effective therapeutic combinations for clinical use, enabling pharmaceutical companies to create more effective and affordable cancer treatments.
The mixed experimental and digital health startup aims to lead the Precision Oncology market, capturing 8% of an industry market projected to reach over USD 250 billion by 2030 for drugs in pre-clinical development and Phase I clinical trials.
Calico Biosystems will invest the CHF 150,000 from Venture Kick in market entry, innovation, and business growth through strategic partnering.
The Co-Founders, CEO Marie-Agnès Doucey and CSO Riccardo Turrini, are former Unil collaborators with more than 15 years of experience in systems immuno-oncology.
“This exceptional program helped us get the right mindset, kicked us out of our comfort zone, and challenged our vision, pushing us to focus on what matters to achieve a successful business strategy,” stated Riccardo Turrini.
Calico Biosystems’ Co-Founders: CSO Riccardo Turrini and CEO Marie-Agnès Doucey
The mixed experimental and digital health startup aims to lead the Precision Oncology market, capturing 8% of an industry market projected to reach over USD 250 billion by 2030 for drugs in pre-clinical development and Phase I clinical trials.
Calico Biosystems will invest the CHF 150,000 from Venture Kick in market entry, innovation, and business growth through strategic partnering.
The Co-Founders, CEO Marie-Agnès Doucey and CSO Riccardo Turrini, are former Unil collaborators with more than 15 years of experience in systems immuno-oncology.
“This exceptional program helped us get the right mindset, kicked us out of our comfort zone, and challenged our vision, pushing us to focus on what matters to achieve a successful business strategy,” stated Riccardo Turrini.
Calico Biosystems’ Co-Founders: CSO Riccardo Turrini and CEO Marie-Agnès Doucey